Background-The cause and consequences of impaired adrenergic signaling in right ventricular failure/hypertrophy (RVH) are poorly understood. We hypothesized that G protein-coupled receptor kinase-2 (GRK2)-mediated uncoupling of ␤-adrenergic receptor signaling impairs inotropic reserve. The implications of right ventricular (RV) adrenergic remodeling for inotrope selection and the therapeutic benefit of interrupting G␤␥-GRK2 interaction, using gallein, were tested. Methods and Results-Chamber-specificity and cellular localization of adrenergic remodeling were compared in rodent RVH associated with pulmonary arterial hypertension (PAH-RVH; SU5416ϩchronic-hypoxia or Monocrotaline) versus pulmonary artery banding-induced RVH (PAB-RVH). Results were corroborated in RV arrays from 10 PAH patients versus controls. Inotropic reserve was assessed in RV-and left ventricular-Langendorff models and in vivo. Gallein therapy (1.8 mg/kg/day ϫ2-weeks) was assessed. Despite similar RVH, cardiac output (58.3Ϯ4.9 versus 82.9Ϯ4.8 mL/min; PϽ0.001) and treadmill distance (41.5Ϯ11.6 versus 244.1Ϯ12.4 m; PϽ0.001) were lower in PAH-RVH versus PAB-RVH. In PAH-RVH versus PAB-RVH there was greater downregulation of ␤1-, ␣1-and dopamine-1 receptors, more left ventricular involvement, and greater impairment of RV contractile reserve. RV GRK2 activity increased in parallel with a reduction in both adrenergic receptor expression and inotrope-stimulated cAMP levels (PϽ0.01). ␤1-receptor downregulation also occurred in human PAH-RVH. Dobutamine was superior to dopamine as an RV inotrope, both ex vivo and in vivo. Conclusions-GRK2-mediated desensitization-downregulation of adrenergic and dopaminergic receptors impairs inotropic reserve in PAH-RVH. Acute inotropic support in RVH is best accomplished by dobutamine, reflecting its better coupling to adenylyl cyclase and the reliance of dopamine on dopamine-1-receptor signaling, which is impaired in RVH. Inhibiting G␤␥-GRK2 interactions has therapeutic benefit in RVH. (Circulation. 2012;126:2859-2869.)
R ight ventricular hypertrophy (RVH) occurs in response to pressure overload in congenital heart diseases, such as pulmonic stenosis, and in pulmonary arterial hypertension (PAH). Severe and prolonged right ventricular (RV) pressure overload often results in RV failure (RVF), which is a leading cause of death in PAH 1 and congenital heart disease. 2 We hypothesized that reduced contractile reserve in RVH, particularly when associated with PAH (PAH-RVH), reflects a broad downregulation and desensitization of adrenoreceptors and dopamine receptors by G protein-coupled receptor kinase-2 (GRK2). Using rodent models of RVH and human ventricular tissue from PAH patients with RVF, we explored the molecular basis for impaired RV adrenergic signaling. In addition, we assessed whether changes in adrenergic signaling involved the left ventricle (LV). Throughout the study, we compared findings in RVH induced by pulmonary artery banding (PAB-RVH) with those in PAH-RVH. This comparison was chosen because PAB-RVH is well tolerated, suggesting it is adaptive, whereas PAH-RVH is poorly tolerated with a greater predisposition to RVF and premature death, suggesting it is maladaptive. Likewise, a human equivalent of PAB-RVH, as occurs in pulmonic stenosis, is better tolerated than the RVH associated with PAH. Because there is little scientific guidance for the selection of an optimal inotrope to support the failing RV in PAH, we also evaluated the consequences of adrenergic remodeling in RVH for the choice of inotropic agent. Finally, we tested a new therapeutic strategy to improve adrenergic signaling and RV function in experimental RVH, namely interruption of G␤␥-GRK2 signaling using a small molecule inhibitor, gallein.
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In initial experiments, we defined the molecular basis for impaired adrenergic and dopaminergic signaling in RVH and profiled receptor expression in both ventricles. The functional significance of adrenergic and dopaminergic receptor downregulation was assessed using RV and LV Langendorff preparations. Next, we compared inotropes that are commonly used in clinical practice to determine which is optimal for acute support of the hypertrophied RV. These experiments were conducted ex vivo (using RV-and LV-Langendorff preparations) and in vivo. Subsequently, we assessed the role of GRK2 in mediating adrenergic receptor downregulation. In left ventricular failure (LVF), circulating catecholamine levels are elevated and excess G␤␥ signaling recruits cytosolic GRK2 to agonist-stimulated ␤-adrenoceptors (␤-AR), promoting receptor downregulation and desensitization. 3 GRK2 also regulates the expression and function of ␣-adrenoceptors and dopamine-1A receptors. 4, 5 Likewise, in LV hypertrophy, interaction between GRK2 and G␤␥ desensitizes ␤-ARs 6 and, together with Gq-coupled receptor signaling, contributes to the pathophysiology. 7 Although much is known about the adrenergic system in LVF/LV hypertrophy, a recent National Heart, Lung, and Blood Institute position paper emphasized the need to understand RVH and RVF, noting these entities differ significantly from LV hypertrophy/LVF. 8 Differences between PAH-RVF and LVF include a higher in-hospital mortality rates for an episode of decompensation (14% for PAH-RVF versus 3% to 5% for LVF). 1 In addition, the pathogenesis of PAH-RVF (eg, anorexigens, congenital heart disease, collagen vascular disease) differs from that of LVF (systemic hypertension, idiopathic dilated cardiomyopathy, valvular disease, and coronary artery disease). PAH-RVF also differs pathophysiologically, having unique features that limit cardiac output (CO; eg, a high, fixed transpulmonary gradient, RV compression of the LV and decreased RV perfusion attributable to reduced coronary perfusion pressure or vascular rarefaction 9 ). Finally, several approved PAH therapies have no benefit in LVF (endothelin antagonists 10 ) or are harmful (epoprostenol 11 ). To explore the translational relevance of the impaired adrenergic signaling, we tested the therapeutic value of interrupting the interaction between G␤␥ and GRK2 in vivo, using a small molecule inhibitor (gallein). 3 We discovered that GRK2-mediated adrenergic remodeling, notably downregulation and desensitization of the ␤1-AR, impairs inotropic reserve. In adaptive RVH models the adrenergic remodeling is largely confined to the RV; however, in PAH-RVH the abnormalities affect the LV. In all models dobutamine is a superior inotrope versus dopamine.
The finding that CO and exercise capacity can be increased by targeting GRK1-G␤␥ interaction may be clinically relevant. Key results in the rodents were confirmed in human tissues.
Methods and Materials
All authors have read and agreed to the manuscript as written.
Experimental Protocols
The University of Chicago Institutional Animal Care and Use Committee approved all protocols. Three RVH models were created in adult male Sprague-Dawley rats: (1) PAB-RVH, (2) PAH-RVH, induced by SU5416ϩchronic hypoxia (CHϩSU) or Monocrotaline (MCT). End points were studied after 4 weeks in each model (nϭ8 -13). The infusion of inotropes was primarily performed in additional cohorts of Control and MCT (nϭ7-12/group), although results were confirmed in CHϩSU (nϭ5) and PAB (nϭ2). In additional cohorts, gallein (1.8 mg/kg/day, Tocris Bioscience, Ellisville, MO) was injected intraperitoneally for 2 weeks, beginning 2 weeks after Monocrotaline injection or PAB surgery (nϭ6 -9).
Experimental Models
The PAB model has been described previously 12 (see online-only Data Supplement). In CHϩSU model, rats (260 -280 g) were injected with the VEGF receptor antagonist SU5416 (20 mg/kg, subcutaneously) and then transferred to hypoxic cages (Ϸ10% oxygen, Biospherix, Lacon, NY) for 4-weeks. In the MCT model, rats (260 -280 g) were injected with monocrotaline (60 mg/kg, subcutaneously; Sigma, St. Louis, MO).
Treadmill Distance
Exercise capacity was tested by measuring maximal distance run on a motorized treadmill, as described 12 (see online-only Data Supplement).
Echocardiography
A Vevo 2100 (Visual Sonics, Ontario, Canada) was used to assess CO, stroke volume (SV), and RV function, as described 13 (see online-only Data Supplement).
Right Ventricular Hypertrophy
RVH was measured postmortem as the ratio of RV/(LVϩseptum) weight.
RV and LV Langendorff Models
The Langendorff models were performed as previously described 12 (see online-only Data Supplement).
Thermodilution Cardiac Output
Thermodilution CO was measured as previously described 13 (see online-only Data Supplement).
Right Heart Catheterization With Infusion of Dopamine and Dobutamine
Rats were anesthetized (3% of isoflurane with 95% oxygen), intubated, and placed on a heated surgical table (37°C). A 1.9F pressure-volume catheter (Scisense Inc, London, Ontario, Canada) was inserted into RV via the right jugular vein to monitor the RV systolic pressure (RVSP) and volume. After stabilization, a pressurevolume signal was continuously recorded at sampling rate of 1000/s using an MPVS-300 (ADInstruments; Colorado Springs, CO) coupled to a PowerLab8/30 converter (ADInstruments). Dopamine or dobutamine was infused via the left jugular vein in 1 mL over 5-minute at clinically relevant doses 14 (11 and 22 g/kg/min), using a syringe pump (Cole-Parmer, Vernon Hills, IL). Heart rate (HR), RVSP, CO, ejection fraction, and SV were computed using pressurevolume analysis software (Labchart7.2; ADInstruments).
Laser Capture Microdissection
RV tissue was embedded in OCT compound (Sakura Finetek, Torrance, CA) and stored at Ϫ80°C. RV sections 7 m thick were stained with the Arcturus HistoGene frozen-section staining kit (Applied Biosystems, Carlsbad, CA). RV myocytes and intramyocardial RV coronary arteries were harvested from fresh cryosections using the Palm MicroBeam system (Carl Zeiss, Thornwood, NY), and mRNA was isolated immediately. Each sample consisted of 20 to 30 RV myocytes or intramyocardial coronary arteries. Tissue localization of mRNA expression was guided visually and confirmed by enriched expression of tissue-specific reporters (␣-myosin heavy chain for cardiomyocytes versus CD31 for vasculature).
qRT-PCR, Immunoblot, and Immunofluorescence
These techniques were performed as described previously (see online-only Data Supplement). 12 
Human Tissue Microarrays
Immunohistochemistry was performed on 1-mm RV cores from formalin-fixed, paraffin-embedded archival material of autopsied PAH patients (nϭ10) or age-matched non-PAH patients (nϭ8). Briefly, samples were arranged on a microscope slide, creating a tissue microarray (see text and Table I in the online-only Data Supplement for immunofluorescence technique and patient demographics). Consent was obtained for each autopsy, and the institutional review board was notified of the research performed on anonymized specimens from deceased individuals.
GRK2 Activity (Rhodopsin Phosphorylation) and cAMP levels (ELISA)
The heart was isolated from anesthetized rats, mounted in the Langendorff apparatus, and perfused with oxygenated Krebs-Henseleit buffer for 10 minutes. Hearts were then perfused for 2 minutes with vehicle or dobutamine or dopamine (10 mol/L each). The RV was isolated and stored at Ϫ80°C for measurement of cAMP levels and GRK2 activity. These assays were performed as previously described 15 (see online-only Data Supplement).
Statistics and Sample Size
Values were expressed as meanϮSEM. Sample sizes are shown in each figure. Prism 5 (GraphPad Software, La Jolla, CA) was used for data analysis. Comparisons between groups used an ANOVA or unpaired Student t test, as appropriate. Post hoc testing used a Bonferroni correction for multiple comparisons. If the test for normality failed or if the sample was Ͻ5, a Fisher exact test was used. A PϽ0.05 was considered statistically significant.
Results

Depressed RV Contractile Reserve in RVH
RV mass was similarly increased in all 3 RVH models. In the RV Langendorff model, basal RVSP was greater in PAB than CHϩSU or Monocrotaline (98Ϯ26 versus 71Ϯ7 and 59Ϯ4 mm Hg, Figure 1 ). All RVH models had higher RVSP than control (29Ϯ6 mm Hg, PϽ0.01). The inotropic reserve (whether defined as the fold-or absolute-increase in RVSP caused by 10 nmol/L dobutamine; Figure 1D and Figure I in the online-only Data Supplement) was lower in all RVH groups versus Control and was the lowest in the PAH-RVH models ( Figure 1D ).
Although basal LVSP remained unchanged in PAB, CHϩSU and Monocrotaline (95Ϯ4, 96Ϯ2, 117Ϯ9 mm Hg) versus Control (105Ϯ5 mm Hg; Figure IA in the online-only Data Supplement), the LV inotropic reserve in response to dobutamine (10 nmol/L) was reduced in the PAH-RVH models (PϾ0.05; Figure  IB in the online-only Data Supplement).
CO was reduced in PAB, CHϩSU, and MCT (82.9Ϯ4.8, 71.5Ϯ8.0; 58.3Ϯ4.9 mL/min) versus control (154.2Ϯ16.2 mL/min; Figure 1E ). Likewise, treadmill walking distance was significantly decreased in PAB, CHϩSU, and MCT (244.1Ϯ12.3, 180.0Ϯ25.7, 41.5Ϯ11.6) versus control (406.3Ϯ54.4 m; Figure 1F ). MCT rats had the lowest CO and the shortest treadmill distance.
Comparative Inotropic Potency
Whereas the inotropic response of the RV to dobutamine and dopamine was reduced in all RVH groups versus control Greater impairment of RV function, exercise capacity, and contractile reserve in PAH-RVH versus PAB-RVH. A and B, Representative images and mean data showing similar severity of RVH in all models. C, Unstimulated RVSP is increased in all RVH models; however, the developed pressure is greatest in the PAB-RVH. D, RV inotropic reserve, though decreased in all RVH groups, is more profoundly decreased in PAH-RVH. E and F, CO and treadmill distance are most severely decreased in MCT. PAH indicates pulmonary arterial hypertension; PAB, pulmonary arterial banding; RVH, right ventricular hypertrophy; RVSP, right ventricular systolic pressure; CO, cardiac output; MCT, monocrotaline; CTR, control; and CHϩSU, SU5416ϩchronic hypoxia.
( Figure 2A-2D ), the inotropic reserve of LV was only depressed in the PAH-RVH models ( Figure 2E-2H) . The dose-response to dobutamine was left-shifted versus dopamine in both the LV and RV in all RVH models ( Figure  2B -2D and 2F-2H), reflecting the superior potency of dobutamine. A similar maximal pressure could be obtained with dopamine (albeit at Ϸ1-log higher dose).
In the RV Langendorff, 10 nmol/L dobutamine, a dose in the clinically-relevant range, increased RVSP more than equimolar dopamine ( Figure IIA in the online-only Data Supplement). Consistent with this, the EC50 of dobutamine was significantly lower than the EC50 of dopamine in all RVH groups (Figure IIB in the online-only Data Supplement). The EC50s were highest in PAH-RVH models, consistent with reduced potency. In the LV, the EC50 of dobutamine was also lower than that of dopamine, but it was unaltered by RVH ( Figure IIC and IID in the online-only Data Supplement).
A dose-response curve to isoproterenol and phenylephrine in control and MCT ( Figure III in the online-only Data Supplement) confirmed that contractile reserve to these inotropes was also reduced in RVH. The potency of inotropes in the RV Langendorff model in MCT hearts was as follows (in descending order): dobutamineϭisoproterenolϾdopamineϾphenylephrine.
Dobutamine Versus Dopamine In Vivo
Baseline HR, CO, and SV were each reduced in MCT versus Control (HR, 294Ϯ5 versus 320Ϯ7 bpm, PϽ0.01; CO, 75Ϯ5 versus 110Ϯ5 mL/min, PϽ0.001; SV, 0.30Ϯ0.02 versus 0.37Ϯ0.03 mL, PϽ0.05; Figure 3A ). In contrast, RVSP was increased in MCT versus control (RVSP, 61Ϯ3 versus 27Ϯ1 mm Hg, PϽ0.001). Dobutamine (22 g/kg/min) caused a greater fold-increase in HR, CO, and SV than dopamine (22 g/kg/min) in MTC (Fold increase: HR, 1.30Ϯ0.01 versus 1.22Ϯ0.05; CO, 1.7Ϯ0.1 versus 1.2Ϯ0.1; SV, 1.4Ϯ0.1 versus 1.2Ϯ0.1; Figure 3B -3D), suggesting greater efficacy of dobutamine versus dopamine. There were no differences in baseline HR, RVSP, CO, dP/dt, or SV in the 2 groups of MTC rats before infusion of dobutamine versus dopamine ( Figure IVA -IVF in the online-only Data Supplement). Similar results, showing the superiority of dobutamine, were obtained at 11 g/kg/min (data not shown). Detailed hemodynamics, obtained using an RV conductance catheter, are summarized in Table II (in the online-only Data Supplement). MTC rats had a markedly elevated RV end diastolic pressure versus control (13Ϯ2 versus 3Ϯ1 mm Hg; PϽ0.01). However, RV dP/dt was not different in MTC versus control (1221Ϯ72 versus 1557Ϯ134 mm Hg/s), and increased further with inotrope infusion (Table II in ever, SCH23390 inhibited dopamine-induced RV inotropy in MTC without altering the response of control RV to dopamine ( Figure 4 ). These findings are consistent with a role for the D1-R in dopamine-induced RV inotropy in RVH.
Downregulation of ␤1-AR, Dopamine Receptors, and ␣1-AR in RVH
RV ␤1-AR mRNA expression was significantly decreased in all RVH models versus control ( Figure 5A ), whereas RV Qualitative immunofluorescence and quantitative immunoblot analysis of membrane proteins confirmed decreased ␤1-AR and D1-R expression in all RVH models (Figures 5E-5F and 6A-6B). Receptor downregulation was most profound in PAH-RVH models ( Figure 5E-5F ).
RV D2-5R mRNA expression was downregulated in CHϩSU and MTC versus control but remained unchanged in PAB (Figure VIB-VIE in the online-only Data Supplement). In the LV, D2-5R mRNA was unaltered in any model ( Figure  6G -6J in the online-only Data Supplement). RV ␣1-AR mRNA (␣1a, ␣1b and ␣1 day) and protein ( Figure VIII in the online-only Data Supplement) were decreased in all RVH groups.
Human RV Tissue Microarray
The expression of ␤1-AR was downregulated in the hypertrophied RV myocytes in RV tissue microarray specimens from PAH patients versus age-and sex-matched controls ( Figure 6C and 6D and Table I in the online-only Data Supplement).
Uncoupling of Adrenergic Receptor Signaling in RVH
Basal RV intracellular cAMP production was similarly decreased in all RVH groups ( Figure 7A ). Increases in cAMP concentrations in response to dobutamine and dopamine (10 nmol/L) were reduced in MTC versus control ( Figure 7B ). Dobutamine caused significantly greater increases in cAMP than dopamine in control and MTC RVs, consistent with better coupling to adenylyl cyclase ( Figure 7B ).
RV GRK2 activity increased in all RVH groups ( Figure  7C ). In control, both inotropes increased GRK2 activity ( Figure 7D ), whereas in MTC, neither inotrope increased GRK2 activity beyond its already elevated basal level, suggesting maximal basal desensitization of the ␤1-AR signaling pathway in this model ( Figure 7D ).
Serial measurements revealed that RV GRK2 activity and expression increased by week 3 and 5 after monocrotaline Figure 5 . ␤1-AR and D1-R are preferentially downregulated in the RV in RVH. A, RV ␤1-AR is downregulated in all RVH models, and D1-R mRNA is downregulated in the RV in PAH-RVH models. B, ␤1-AR mRNA is downregulated in the LV only in CHϩSU, whereas LV D1-R mRNA expression is unchanged in all models. C, RV myocytes and the vessels in the RV were collected by laser capture microdissection. D, mRNA for ␤1-AR and D1-R is decreased in RV myocytes, but not coronary arteries, in all RVH groups. E and F, Representative immunoblot and mean data show decreased expression of ␤1-AR and D1-R in the plasma membrane fraction of homogenized RV tissue. The downregulation of ␤1-AR and D1-R is more severe in PAH-RVH models than in PAB-RVH. RV indicates right ventricular; LV, left ventricular; AR, adrenoceptor; PAH, pulmonary arterial hypertension; PAB, pulmonary arterial banding; RVH, right ventricular hypertrophy; MCT, monocrotaline; CTR, control; and CHϩSU, SU5416ϩchronic hypoxia.
injection, respectively (Figure IXA-IXC in the online-only Data Supplement). RV expression of ␤1-AR and D1-R mRNA began to decrease at week 3 and continued to decline thereafter ( Figure IXE and IXF in the online-only Data Supplement). Thus, GRK2 activation and receptor downregulation occur concomitantly, consistent with the proposed role for GRK2 in adrenergic remodeling.
In Vivo Gallein Therapy
In PAB, 2 weeks of gallein treatment increased treadmill distance and cardiac index. Gallein caused a statistically insignificant trend toward increased tricuspid annular plane systolic excursion, a measure of RV function (PϾ0.05; Figure 8A-8D) . In MTC, gallein significantly increased CO and tricuspid annular plane systolic excursion on echocardiography (PϽ0.01; Figure 8C and 8D); however, RV/ LVϩseptum ratio, the catheterization and treadmill data, though trending toward benefit, were not statistically significant (PϾ0.05; Figure 8A and 8B and Figure XA and XB in the online-only Data Supplement). To confirm that gallein indeed had an effect on GRK2, we measured phospho-670 GRK2 and total GRK2 protein. 
Discussion
The molecular basis for reduced RV inotropy and impaired adrenergic signaling in severe RVH was studied in 2 types of experimental RVH, 1 associated with PAH (CHϩSU or MTC) and the other a model of pure RVH (PAB). The use of these different RVH models allowed identification of the derangements of adrenergic and dopaminergic signaling that are common to all forms of RVH versus those that are model-specific. In this regard, although the ␤1-AR downregulation was universal, it was more severe and extensive (involving the LV) in the maladaptive models, those with PAH-RVH. We refer to these models as being maladaptive because exercise capacity and CO were more depressed than in PAB-RVH, even though the severity of the RVH was similar (Figure 1) . 
Molecular Basis and Chamber Specificity of Impaired Adrenergic and Dopaminergic Signaling in RVH
In the current study, both mRNA and protein expression of adrenergic and dopaminergic receptors were downregulated in all RVH models (Figures 5 and 6 ). Downregulation and desensitization of adrenergic (␤1-and ␣1-adrenoreceptors) and dopaminergic receptors (D1-R) primarily occurred in RV myocytes ( Figures 5 and 6 and Figures VI and VIII in the online-only Data Supplement). Although it may seem intuitive that the downregulation of ␤1-AR and D1-R would occur in RV myocytes, there are other candidate cells in the RV (vascular cells, fibroblasts, and inflammatory cells). Laser capture microdissection provided the precision to identify the affected cell type as the RV myocyte ( Figure 5C and 5D and Figure VII in the online-only Data Supplement). Decreased expression of the ␤1-AR is also evident in the RV myocytes of humans with PAH ( Figure 6C and 6D) , confirming previous studies in rodents 17 and human. 18 The pathological relevance of this adrenergic remodeling is supported by the observation that the magnitude of the reduction in ␤1-AR expression is greatest in PAH-RVH models, and these models have the greatest impairment of contractile reserve (Figures 5  and 6 ).
Bristow et al 18 examined the ␤-adrenergic system in patients with idiopathic PAH who either had RVF or were well compensated. Only those with RVF had decreased RV ␤-AR density. This PAH-RVF subset displayed depletion of norepinephrine and decreased adenylyl cyclase responsiveness to ␤-agonists, consistent with our findings in rats with PAH-RVH. Noontens et al 19 demonstrated high circulating catecholamine levels in PAH-RVF patients, noting the loss of the normal ability to augment catecholamine levels with exercise. Likewise, in PAH-RVH rats, we found that inotropic stimulation could not further augment RV GRK2 activity beyond the elevated basal levels (Figure 7 ). Bristow et al reported that in humans with PAH, adrenergic impairment affected only the RV (not the LV). 18 A similar finding was made in a canine RVF model (induced by severe PAB plus tricuspid insufficiency). 20 Consistent with these studies, we report that in PAB-RVH, adrenergic and dopaminergic receptor downregulation is confined to the RV and the depression of RV inotropic reserve is mild. However, in rodent PAH-RVH models, downregulation of adrenergic and dopaminergic receptors was more severe and occurred in both the RV and LV, resulting in biventricular impairment of contractile reserve (Figure 2) .
By evaluating the inotropic responses in both RV and LV Langendorff preparations we were able to assess contractility in each chamber, without the confounding effects of heart rate and afterload. This allowed us to address a longstanding controversy regarding the functional consequences of ␤1-AR downregulation to LV function in PAH. The reduced LV response to dobutamine in MTC and CHϩSU ( Figure 2E-2H ) confirms the physiological relevance of observed downregulation and uncoupling of adrenergic receptors in the LV in these models. The finding of decreased ␤-AR expression in the LV in the PAH-RVH models is consistent with previous studies of monocrotaline rats. 17, 21 LV involvement in PAH-RVH, but not PAB-RVH, likely reflects fundamental differences in how the models were created rather than differences in RVH severity. PAH-RVH models were induced by endothelial toxins (SU5416 or monocrotaline), which likely have vasculotoxic effects beyond the pulmonary circulation, per- haps including the RV vasculature. The concept that the stimuli that initiate PAH may also induce the RV coronary vascular injury is intriguing, particularly as many forms of PAH have evidence of systemic arterial endothelial damage. For example, in scleroderma-associated PAH, patients have circulating cytotoxic autoantibodies that are directed against epitopes in endothelial cells. Interestingly, compared with patients with idiopathic PAH, these scleroderma patients have more severe RV dysfunction, 22 potentially suggesting an effect of the endothelial-targeted antibodies on the RV circulation.
In addition to ␤-1 and ␣-AR downregulation, most dopamine receptor isoforms are also reduced in RVH ( Figures 5  and 6 and Figure VI and VIII in the online-only Data Supplement). Dopamine receptors have been intensively studied in blood vessels and neural and renal tissues 23 ; however, only recently was the expression of D1, D2, D4, and D5 receptors reported in human hearts. 24 Their function remained uncertain, although Li et al showed that D1-R activation modulates ischemia/reperfusion-induced apoptosis in neonatal rat cardiomyocytes. 25 Dopamine receptors are pharmacologically classified into two classes: D1-like (which stimulate adenylyl cyclase) and D2-like (which inhibit adenylyl cyclase). The pattern of depressed dopamine receptor expression observed in RVH would be predicted to reduce D1-signaling and might contribute to the observed impairment in cAMP production. To test the relevance of D1-R downregulation to impaired contractile reserve we administered a selective D1-R antagonist, SCH23390. This inhibitor selectively reduced dopamine contractility in RVH without affecting the response of dopamine in control hearts or altering the response to dobutamine (Figure 4 ). This reveals for the first time that D1-R contributes to dopamine-induced RV inotropy. Thus, the loss of dopamine receptors in experimental RVH likely contributed to the reduced contractile response to dopamine, both in vitro and in vivo (Figures 2 and  3 and Figures I, II, and IV in the online-only Data Supplement). As with the ␤1-AR, D1-R expression is most depressed in PAH-RVH models, although in contrast D1-R expression is not reduced in the LV in any model (Figures 5  and 6 ).
Optimal Inotropic Support in RVH
Dobutamine was shown to be more effective in increasing CO than dopamine in all RVH models, as a result of both superior coupling to adenylyl cyclase (as indicated by the greater evoked increase in cAMP) and the loss of D1-R expression in RVH, which exclusively impairs dopamine contractility ( Figures 2-4 and 7) . In RV and LV Langendorff models, the dose-response curves of dobutamine were leftshifted compared with those of dopamine (Figure 2 ). At equimolar doses (10 nmol/L), dobutamine induced greater contractility than dopamine in all RVH models (and even in the normal RV; Figure II in the online-only Data Supplement). These data indicate that dobutamine is superior to dopamine as an RV inotrope. Consistent with observations in left heart failure, 26 dobutamine caused a greater increase in CO (resulting from greater increases in SV and HR) than dopamine ( Figure 3) . However, dopamine is better at increasing dP/dt in vivo (Table II in and dobutamine tends to increase ejection fraction more than dopamine (PϾ0.05; Table II in the online-only Data Supplement) . Although dobutamine is a better inotrope than dopamine, this comes at some cost of increased heart rate ( Figure  3 ). However, a significant portion of the net effect of dobutamine on CO is related to its ability to increase stroke volume. The greater increase in RV contractility in the RV Langendorff preparation also proves that increased heart rate is not the only reason for the superior augmentation of CO by dobutamine. The reduced RV response to dopamine reflects the combined consequence of alterations in adrenergic signaling in RVH, some of which uniquely or differentially impair the response to dopamine versus dobutamine. Impaired RV responses to dopamine in PAH-RVH reflect the combination of decreased ␤1-AR expression (which also effect dobutamine; Figures 5 and 6 ), inferior coupling of dopamine to adenylyl cyclase (less cAMP production; Figure  7 ), and the loss of D1-R-dependent contractility (which only affects dopamine; Figure 4 ). The greater elevation of cAMP concentrations in response to dobutamine versus dopamine, which we note, has also been reported in human heart failure. 27 
Role of GRK2 in Mediating Receptor Downregulation in RVH
We identified a key role for GRK2 in the adrenergic and dopaminergic receptor downregulation in RVH. GRK2 activity was markedly increased in RVH and was maximal in MTC ( Figure 7 and Figure IV in the online-only Data Supplement), consistent with the severe RVF noted in this model (RVEDP 13Ϯ2 mm Hg; Table II in the online-only Data Supplement). Our findings support those of Leineweber et al, 28 who reported increased GRK2 activity in monocrotaline-RVF.
The Reduced RV Response to Dopamine Reflects Therapeutic Value of Interrupting G␤␥-GRK2 Interaction In Vivo
We explored the therapeutic potential of correcting the adrenergic remodeling. One possible intervention would be the use of an inhibitor of ␤1-AR. The ␣-and ␤-AR inhibitor, carvedilol, improves LV function and survival in patients with LVF. Although ␤-AR antagonists are not approved for treatment of PAH, carvedilol improves RV function in the CHϩSU5416 model. 9 Because of the central role of GRK2 we chose to inhibit G␤␥-GRK2 interaction, using gallein, as an alternative to a ␤-AR antagonist. Gallein inhibits G␤␥ subunit-dependent signaling and has been used for interrupting the interaction between GRK and the G␤␥ subunit of activated G proteins in vitro. 3 Gallein and other peptide G␤␥ inhibitors have been shown to reduce GRK2 expression and improve cardiac function in experimental LVF. 3 In the current study, gallein improved cardiac function, as evidenced by improved treadmill distance, tricuspid annular plane systolic excursion, and CO in both PAB-RVH and PAH-RVH (Figure 8 ). Consistent with its proposed mechanism of action, gallein decreased RV GRK2 expression. Further evidence that the beneficial effects of gallein related to its actions on the GRK2 pathway came from the demonstration that it decreased expression of activated (phosphorylated) ERK1/2, a kinase that regulates GRK2 activity ( Figure 8I and 8J and Figure XG and XH in the online-only Data Supplement). The relationship between ERK1/2 and GRK is complex. Some studies suggest that ERK is upstream and phosphorylates ␤-arrestin and GRK, 29 whereas others place ERK downstream from GRK. 30 
Limitations
We did not explore the mechanism for GRK2 activation. However, previous studies suggest that in states of hypertrophy and autonomic activation, protein kinase C phosphorylates and activates GRK2. 15 There are some limitations to the gallein experiments. First, gallein undoubtedly has effects in addition to G␤␥ inhibition. Second, at the doses used, gallein did not restore ␤1-AR protein expression, although it did inhibit the expression of GRK2. The regimen that restored ␤1-AR expression in LV failure (30 mg/kg/d for 3-4 weeks 3 ) was more intense than what we used (1.8 mg/kg/d for 2 weeks). However, whereas gallein (0.1 mol/L) acutely increases contractility in Control and PAB, it slightly decreased contractility in MTC ( Figure XIC and XID in the online-only Data Supplement), suggesting lower doses may be required in PAH-RVH. Third, although gallein increased CO in PAB rats (a model devoid of pulmonary or systemic vascular disease), studies are needed to assess possible effects of gallein on the pulmonary and systemic vasculature.
Conclusion
GRK2-mediated adrenergic remodeling of the RV and LV contributes to impaired cardiac function in PAH-RVH. Acute RV inotropic support in PAH-RVH is best accomplished with dobutamine. Inhibition of G␤␥-GRK2 interaction may have promise as a therapy in RVH.
